Is solifenacin succinate safe and effective for the treatment of overactive bladder?

被引：0
作者：
Eilber, Karyn S. [1 ,2 ]
机构：
[1] Harbor Univ Calif, Los Angeles Cty Med Ctr, Div Urol, Los Angeles, CA USA
[2] Harbor Univ Calif, Century Inst Continence, Los Angeles, CA USA
来源：
NATURE CLINICAL PRACTICE UROLOGY | 2008年 / 5卷 / 03期
关键词：
incontinence; overactive bladder; propiverine; solifenacin succinate; urgency;
D O I：
10.1038/ncpuro1040
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [21] Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder
    Fukuda, Takehiko
    Yamanishi, Tomonori
    Uchiyama, Tomoyuki
    Kamai, Takao
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2013, 5 (01) : 11 - 16
  • [22] Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder
    Chapple, Christopher R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (17) : 2421 - 2434
  • [23] Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis
    Ananda, I. Gede Yogi Prema
    Surya, Radika Naufal Hadi
    Surya, Prima Ardiansah
    Putratama, Alfin
    Andhika, Dimas Panca
    UROLOGY ANNALS, 2025, 17 (01) : 2 - 8
  • [24] Analysis of overactive bladder symptoms after ceasing solifenacin treatment
    Wlazlak, Edyta
    Suzin, Jacek
    Dunicz-Sokolowska, Aldona
    Bugaj, Andrzej Marcin
    Surkont, Grzegorz
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (03): : 278 - 282
  • [25] Once-daily solifenacin succinate or extended-release tolterodine for overactive bladder syndrome?
    Wyndaele, JJ
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (04): : 184 - 185
  • [26] A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial
    Chapple, CR
    Martinez-Garcia, R
    Selvaggi, L
    Toozs-Hobson, P
    Warnack, W
    Drogendijk, T
    Wright, DM
    Bolodeoku, J
    EUROPEAN UROLOGY, 2005, 48 (03) : 464 - 470
  • [27] Tamsulosin and Solifenacin in the treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
    Wang, Hui
    Chang, Yanhua
    Liang, Hui
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2017, 33 (04) : 988 - 992
  • [28] Risk Factors for the Failure of Antimuscarinic Treatment With Solifenacin in Women With Overactive Bladder
    Serati, Maurizio
    Braga, Andrea
    Siesto, Gabriele
    Sorice, Paola
    Cattoni, Elena
    Uccella, Stefano
    Cromi, Antonella
    Salvatore, Stefano
    Ghezzi, Fabio
    UROLOGY, 2013, 82 (05) : 1044 - 1048
  • [29] Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder
    Ciftci, Seyfettin
    Ozkurkcugil, Cuneyd
    Yilmaz, Hasan
    Ustuner, Murat
    Yavuz, Ufuk
    Yuksekkaya, Mustafa
    Cekmen, Mustafa Baki
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2016, 27 (02) : 275 - 280
  • [30] Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder
    Newgreen, Donald
    Bosman, Brigitte
    Hollestein-Havelaar, Adriana
    Dahler, Ellen
    Besuyen, Robin
    Snijder, Robert
    Sawyer, Will
    Rittig, Soren
    Bolduc, Stephane
    JOURNAL OF UROLOGY, 2017, 198 (04) : 928 - 936
12345